Drug boosts hemoglobin but not survival in heart failure study

03/12/2013 | Forbes

In patients with systolic heart failure and mild-to-moderate anemia, treatment with the erythropoiesis-stimulating agent Aranesp, or darbepoetin alfa, boosted hemoglobin levels but did not improve patient outcomes, according to a study in the New England Journal of Medicine. "Our findings suggest that the hemoglobin level, like other surrogates, is simply a marker of poor prognosis in heart failure rather than a therapeutic target," researchers said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC